HGH Fragment 176-191 vs Sermorelin
Moderate Research vs Well Studied
monitor Mechanism-based · 47% Both HGH Fragment 176-191 and Sermorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
HGH Fragment 176-191 Sermorelin
Weight 1,817.1 Da 3,358 Da
Half-life 15-20 minutes 10-12 minutes
Chain 16 amino acids 29 amino acids
Type hGH C-terminal fragment (176-191) GHRH analog
Key Benefits
HGH Fragment 176-191
01 Stimulates lipolysis without growth hormone side effects
02 Does not affect blood glucose or insulin sensitivity
03 Does not increase IGF-1 levels
04 Selectively targets fat metabolism
05 No impact on bone or organ growth
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
HGH Fragment 176-191
250-500mcg / Twice daily (fasted)
Fat loss - Standard 250mcg Twice daily (morning fasted + pre-bed)
Enhanced fat loss 500mcg Twice daily (morning fasted + pre-bed)
Conservative start 250mcg Once daily (morning, fasted)
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
HGH Fragment 176-191
Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
HGH Fragment 176-191 Sermorelin
Status Moderate Research Well Studied
References 4 studies 5 studies
Latest 2014 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.